Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

No benefit for adjuvant durvalumab in completely resected NSCLC

ESMO 2024: Highlights and analysis

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy